|
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
CARDIFF-BY-THE-SEA, Calif., Jan. 12, 2026 /PRNewswire/ -- Field Medical Inc., a clinical-stage medical technology company advancing a versatile, next-generation pulsed field ablation (PFA) platform designed to support both ventricular tachycardia (VT) and atrial fibrillation (AF) ablation, today announced that its founder, Steven Mickelsen, MD, will present at the 44th annual J.P. Morgan Healthcare Conference on Thursday, Jan. 15, 2026, at 10 a.m. PT at The Westin St. Francis in San Francisco.
The presentation will feature a company overview, including the FieldForce™ PFA platform, clinical progress in VT, the Field-PULSE AF study, and plans for the upcoming pivotal VT trial.
Field Medical's leadership team will be available for meetings during the conference. To request a meeting, please email ir@fieldmedicalinc.com.
About Field Medical® Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce™ Ablation System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X and YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Contacts
Media
Holly Windler
619.929.1275
media@fieldmedicalinc.com
Investor Relations
ir@fieldmedicalinc.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Field Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
|
- Formula E concluded its inaugural Madrid E-Prix at the Circuito del Jarama, where Hankook's iON Race operated consistently across the championship's longest circuit
- The race marked the first single-header event to feature PIT BOOST, adding a new strategic layer alongside a revised ATTACK MODE
- Hankook also engaged fans at the Hankook booth in the Fan Village, highlighting its iON EV tire technology
MADRID, March 23, 2026 /PRNewswire/ -- Global leading tire company Hankook Tire & Technology (hereafter Hankook), the exclusive tire supplier to the ABB FIA Formula E World Championship, equipped all teams as Formula E staged the 2026 CUPRA Raval Madrid E-Prix at the historic Circuito del Jarama. The race unfolded as a strategically complex contest shaped by Pit Boost, revised Attack Mode, and the demands of the championship's longest circuit.
Round 6 of Season 12 unfolded over 23 laps of the 3.934 km Jarama circuit, where fast-flowing corners and plenty of elevation changes placed a premium on energy management and strategic execution. The first single-header use of PIT BOOST, alongside a revised ATTACK MODE, added an additional strategic dimension for teams.
António Félix Da Costa led Jaguar TCS Racing to victory at the inaugural Madrid E-Prix, securing a 1–2 finish ahead of teammate Mitch Evans, while Pascal Wehrlein completed the podium for Porsche Formula E Team. Strategy and energy management played a key role across the 23-lap race.
Throughout the race, Hankook supplied all teams with its iON Race tire, which delivered stable grip and controlled thermal performance as track conditions evolved across the weekend. Jarama's fast directional changes and sustained cornering loads demanded predictable warm-up characteristics and consistent traction over the full race distance. Despite limited historical race data at the venue, the tire's balanced performance window enabled teams to commit to their PIT BOOST and ATTACK MODE strategies with confidence.
"The Madrid E-Prix offered a valuable opportunity to see how teams adapted their strategy on Formula E's longest circuit," said Manfred Sandbichler, Senior Director of Hankook Motorsport. "With PIT BOOST and a revised ATTACK MODE influencing race dynamics, tire consistency was an important factor as teams managed energy and race pace across the 23-lap distance. Insights from Jarama will contribute to our ongoing collaboration with the championship as the season continues."
With Round 6 completed in Madrid, the ABB FIA Formula E World Championship now turns to Rounds 7 and 8 in Berlin, where teams will face a contrasting challenge on the championship's established Tempelhof circuit.
- Formula E concluded its inaugural Madrid E-Prix at the Circuito del Jarama, where Hankook's iON Race operated consistently across the championship's longest circuit
- The race marked the first single-header event to feature PIT BOOST, adding a new strategic layer alongside a revised ATTACK MODE
- Hankook also engaged fans at the Hankook booth in the Fan Village, highlighting its iON EV tire technology
MADRID, March 23, 2026 /PRNewswire/ -- Global leading tire company Hankook Tire & Technology (hereafter Hankook), the exclusive tire supplier to the ABB FIA Formula E World Championship, equipped all teams as Formula E staged the 2026 CUPRA Raval Madrid E-Prix at the historic Circuito del Jarama. The race unfolded as a strategically complex contest shaped by Pit Boost, revised Attack Mode, and the demands of the championship's longest circuit.
Round 6 of Season 12 unfolded over 23 laps of the 3.934 km Jarama circuit, where fast-flowing corners and plenty of elevation changes placed a premium on energy management and strategic execution. The first single-header use of PIT BOOST, alongside a revised ATTACK MODE, added an additional strategic dimension for teams.
António Félix Da Costa led Jaguar TCS Racing to victory at the inaugural Madrid E-Prix, securing a 1–2 finish ahead of teammate Mitch Evans, while Pascal Wehrlein completed the podium for Porsche Formula E Team. Strategy and energy management played a key role across the 23-lap race.
Throughout the race, Hankook supplied all teams with its iON Race tire, which delivered stable grip and controlled thermal performance as track conditions evolved across the weekend. Jarama's fast directional changes and sustained cornering loads demanded predictable warm-up characteristics and consistent traction over the full race distance. Despite limited historical race data at the venue, the tire's balanced performance window enabled teams to commit to their PIT BOOST and ATTACK MODE strategies with confidence.
"The Madrid E-Prix offered a valuable opportunity to see how teams adapted their strategy on Formula E's longest circuit," said Manfred Sandbichler, Senior Director of Hankook Motorsport. "With PIT BOOST and a revised ATTACK MODE influencing race dynamics, tire consistency was an important factor as teams managed energy and race pace across the 23-lap distance. Insights from Jarama will contribute to our ongoing collaboration with the championship as the season continues."
With Round 6 completed in Madrid, the ABB FIA Formula E World Championship now turns to Rounds 7 and 8 in Berlin, where teams will face a contrasting challenge on the championship's established Tempelhof circuit.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Hankook's iON Race Supports Competitive Racing at Historic Madrid E-Prix
